Stock Price Quote

ALEMBIC PHARMACEUTICALS LTD.

NSE : APLLTDBSE : 533573ISIN CODE : INE901L01018Industry : Pharmaceuticals & DrugsHouse : Alembic
BSE938.008 (+0.86 %)
PREV CLOSE ( ) 930.00
OPEN PRICE ( ) 933.55
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 3285
TODAY'S LOW / HIGH ( )915.25 948.95
52 WK LOW / HIGH ( )528.95 1093.05
NSE938.357.3 (+0.78 %)
PREV CLOSE( ) 931.05
OPEN PRICE ( ) 929.95
BID PRICE (QTY) 938.35 (58)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 69069
TODAY'S LOW / HIGH( ) 913.95 948.75
52 WK LOW / HIGH ( )527.35 1094
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 16-06 2010
Management Info
Chirayu Amin - Chairman Shaunak Amin - Managing Director
Registered Office

Address Alembic Road, , ,
Vadodara,
Gujarat-390003

Phone 0265 - 2280550 / 2280880

Email alembic@alembic.co.in

Website www.alembicpharmaceuticals.com

Registrars Details
Link Intime India Pvt Ltd.
Geetakunu, 1, Bhakti Nagar Society,Behind ABS Tower,Old Padra Road,Vadodara
Listing : BSE, NSE, MCX

NEWS

16Apr Alembic Pharmaceuticals informs about
Alembic Pharmaceuticals has informed that it enclosed the intimation dat..
06Apr Alembic Pharmaceuticals informs about
Alembic Pharmaceuticals has informed that Alembic Global Holding SA, who..
02Apr Alembic Pharma rises on getting tentat
Alembic Pharmaceuticals is currently trading at Rs. 1013.55, up by 8.70..
01Apr Alembic Pharma gets tentative USFDA’s
Alembic Pharmaceuticals has received tentative approval for generic Ribo..
01Apr Alembic Pharmaceuticals informs about
Alembic Pharmaceuticals has informed that the Company has received one U..

Financials

in Millions
QTR Dec 23 ANNUAL 23
Net Profit2332.43467.3
Gross Profit 2567 3459.3
Operating Profit 3404.46678.8
Net Sales 15883.951490

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Bharat Parenterals (BSE)
peergroup  1455.20 (10.00%)
M.Cap ( in Cr)846.88
Solara Active Pharma (BSE)
peergroup  551.45 (16.32%)
M.Cap ( in Cr)1985.01
Abbott India (BSE)
peergroup  26131.85 (0.29%)
M.Cap ( in Cr)55528.36
Windlas Biotech (BSE)
peergroup  555.05 (6.97%)
M.Cap ( in Cr)1154.42
Concord Biotech (BSE)
peergroup  1595.25 (1.05%)
M.Cap ( in Cr)16688.90

Shareholding Pattern

MUTUAL FUNDS/UTI 7.82%
FI/BANKS/INSURANCE 7.13%
PROMOTERS 69.61%
NON-INSTITUTION 10.54%
GOVERNMENT 0%
FII 0%

About Alembic Pharmaceuticals Ltd.

Alembic Pharmaceuticals Ltd. was incorporated in the year 2010. Its today's share price is 938. Its current market capitalisation stands at Rs 18437.62 Cr. In the latest quarter, company has reported Gross Sales of Rs. 51490 Cr and Total Income of Rs.51528.5 Cr. The company's management includes Manisha Saraf, Jai Diwanji, Ashok Kumar Barat, Archana Hingorani, R K Baheti, Shaunak Amin, Pranav Amin, Chirayu Amin.

It is listed on the BSE with a BSE Code of 533573 , NSE with an NSE Symbol of APLLTD and ISIN of INE901L01018. It's Registered office is at Alembic Road, , Vadodara-390003, Gujarat. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are KC Mehta & Co, KC Mehta & Co LLP, KS Aiyar & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.